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Abstract: Trimethylamine N-oxide (TMAO) is an organic compound derived from dietary choline 10 
and L-carnitine. It behaves as an osmolyte, a protein stabilizer and an electron acceptor, showing 11 
different biological functions in different animals. Recent works point out that in humans high 12 
circulating levels of TMAO are related with the progression of atherosclerosis and other 13 
cardiovascular diseases. Nevertheless, studies on a direct role of TMAO on cardiomyocytes 14 
parameters are still limited. This work focuses on the effects of TMAO on isolated adult rat 15 
cardiomyocytes. TMAO both 100µM and 10mM, from 1 to 24 h of treatment, does not affect cell 16 
viability, sarcomere length, intracellular ROS and mitochondrial membrane potential. Furthermore, 17 
the simultaneous treatment with TMAO and known cardiac insults, H2O2 or Doxorubicin, does not 18 
affect the effect of the treatment. In conclusion, TMAO cannot be considered a direct cause or an 19 
exacerbating risk factor of cardiac damage at the cellular level in acute conditions.  20 
Keywords: Trimethylamine N-oxide; cardiomyocytes; cardiotoxicity; ROS; mitochondrial 21 
membrane potential  22 
 23 
1. Introduction 24 
Trimethylamine N-oxide (TMAO) is an amine oxide directly introduced through the diet or 25 
synthetized from its precursors, primarily L-carnitine and choline, that are transformed into 26 
trimethylamine (TMA) by the gut microbiota. Once absorbed, TMA in most mammals is oxidized by 27 
hepatic FMOs to form TMAO which enters the systemic circulation. Several studies illustrates 28 
different biological functions of TMAO in other animals. In elasmobranchs and deep sea fishes it acts 29 
as an osmolyte able to counteract either osmotic or hydrostatic pressure. It is a protein stabilizer 30 
preserving protein folding and it also acts as an electron acceptor balancing oxidative stress [1,2]. 31 
TMAO is also reduced to TMA in the anaerobic metabolism of a number of bacteria. Although TMAO 32 
is involved in several reactions within cells, recent studies highlight its detrimental role when present 33 
in high plasmatic concentrations in some mammals. In fact, TMAO seems to be involved in 34 
accelerating endothelial cell senescence, enhancing vascular inflammation and oxidative stress [3,4]; 35 
it also could be involved in the stimulation of platelets hyperreactivity and in the onset of thrombosis, 36 
exacerbating atherosclerotic lesions [5]. Several studies also underline the role of TMAO in the 37 
pathogenesis of type 2 diabetes mellitus [6]. There are limited data on its function in mediating direct 38 
cardiac injuries, and they are mainly focused on its role in the impairment of mitochondrial 39 
metabolism [7] and calcium handling [8]. Instead, recent papers revalue the role of TMAO, 40 
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underlining the emerging debate on its direct effect in causing or exacerbating cardiovascular 41 
diseases (CVD) [9,10]. First criticisms point out that populations that have diets with high 42 
concentrations of TMAO, like those rich in fish products, when compared to Western diets rich in its 43 
precursors, have reduced risks of CVD or diseases assumed to be related to high TMAO plasma levels 44 
[11]. Another study demonstrate that TMAO does not affect macrophage foam cells formation and 45 
lesion progression in ApoE-/- mice expressing human cholesteryl ester transfer protein, suggesting 46 
that the molecule does not worsen atherosclerosis [12]. Furthermore, administration of TMAO seems 47 
to ameliorate symptoms related to streptozotocin induced diabetes in rats and mice, highlighting   48 
no direct contribution of the molecule in exacerbating this condition [13]. Finally, data about TMAO 49 
plasma concentrations in health and pathological subjects are not clear: lack of plasma concentration 50 
ranges of the molecule highlights the difficulties in referring to TMAO as a protective or a damaging 51 
factor in CVD. Starting from these conflicting considerations, aim of this work is to evaluate for the 52 
first time the effect of TMAO in an in vitro model of adult rat cardiomyocytes exposed to different 53 
concentrations of the compound from 1 h to 24 h of treatment. To show whether TMAO exacerbates 54 
or reduces induced cell stress, cardiomyocytes are simultaneously treated with TMAO and H2O2 or 55 
Doxorubicin (DOX). Investigations have been focused to cell viability after TMAO or TMAO and 56 
stressors co-treatment, assessing cell morphology and functionality with α-actinin staining and 57 
specific probes that measure oxidative stress status and mitochondrial membrane potential. 58 
2. Results 59 
2.1 TMAO and cell viability 60 
In order to investigate the effect of TMAO on cell viability, cardiomyocytes are treated with 61 
TMAO 100μM, TMAO 10mM, H2O2 50μM and H2O2 50μM+TMAO 100μM. After 1 h or 24 h of 62 
treatment, cardiomyocytes are labeled with PI and marked nuclei of suffering cells are detected by 63 
confocal microscopy at 568nm. Concentrations used have been taken from literature: TMAO 100µM 64 
is recognized as a marker of cardiovascular risk, TMAO 10mM is over the physiological range and 65 
here tested to detect any effect induced by high concentrations of the compound [14]. As shown in 66 
Figure 1a, there is no effect of TMAO 100µM nor TMAO 10mM at either time of treatment, while 67 
H2O2, here used as positive control, has effects only after 24 h. Simultaneous treatment with H2O2 and 68 
TMAO does not ameliorate nor worsen the effect of the stressor on cell viability (1 h: CTRL: 69 
83.95±6.59, n=3, 52 cells; TMAO 100µM: 85.52±7.01, n=5, 81 cells; TMAO 10mM: 84.08±5.84, n=5, 92 70 
cells; H2O2: 52.92±16.46, n=3, 56 cells; H2O2+TMAO: 50.93±18.50, n=3, 58 cells. 24 h: CTRL: 83.42±2.29, 71 
n=3, 101 cells; TMAO 100µM: 85.66±6.48, n=3, 91 cells; TMAO 10mM: 62.22±10.47 n=3, 119 cells; H2O2: 72 
2.38±2.38, n=3, 82 cells(***P<0.001); H2O2+TMAO: 1.33±1.33, n=3, 41 cells(***P<0.001)). Figure 1b displays 73 
confocal images of cardiomyocytes from a representative experiment of PI staining after 24 h of 74 
treatment. White arrows point out PI-stained, damaged cardiomyocytes. 75 
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Figure 1. Cell viability after TMAO exposure. a) Bar graph of cell viability after 1 h and 24 h of 78 
treatment. Cells viability results reduced only after H2O2 treatment for 24 h, condition not ameliorated 79 
nor worsened by the simultaneous treatment with TMAO (refer to the main text for numerical values). 80 
b) Merged images in bright field and fluorescence of cells treated for 24 h with TMAO 100µM and 81 
TMAO 10mM, H2O2 and H2O2 + TMAO and labeled with propidium iodide (PI) (20X magnification). 82 
White arrows point out PI-stained, damaged cardiomyocytes. 83 
2.2 TMAO and sarcomere length 84 
To evaluate if TMAO is able to alter sarcomere structures after 24 h of treatment, sarcomere 85 
length is measured in α-actinin stained cardiomyocytes. As shown in Figure 2, no changes in 86 
sarcomere length are observed in cells treated with TMAO, while H2O2 50μM used as a positive 87 
control, cause cardiomyocytes shrinkage, condition that is not ameliorated nor worsened by the 88 
simultaneous treatment with TMAO. In cardiomyocytes treated with DOX 1µM for 24 h we do not 89 
observe sarcomere length variations, as in our model DOX treatment is designed to induce a mild 90 
damage preceding cell shortening. Even so, 100µM TMAO does not modify DOX-treated 91 
cardiomyocytes (sarcomere length in µm is: CTRL: 1.69±0.01, n=7, 42 cells; TMAO 100µM: 1.69±0.01, 92 
n=6, 34 cells; TMAO 10mM: 1.67±0.02, n=3, 19 cells; H2O2: 1.22±0.04, n=5, 33 cells (***P<0.001); 93 
H2O2+TMAO: 1.28±0.03, n=3, 24 cells (***P<0.001); DOX: 1.62±0.02, n=3, 16 cells; DOX+TMAO: 94 
1.65±0.01, n=3, 15 cells).  95 
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Figure 2. Sarcomere length after TMAO treatment. a) Confocal microscopy images of fixed cells 97 
labeled for 𝛼-actinin protein (40X magnification). b) Bar graph showing sarcomere length after 24 h of 98 
treatment with TMAO and other stressors: no cell shrinkage is measured when cells are exposed to 99 
different TMAO concentrations (refer to the main text for numerical values). 100 
2.3 TMAO and intracellular Reactive Oxygen Species (ROS)  101 
In order to determine a variation in total ROS produced after treatment with TMAO for 1 h, 3 h 102 
or 24 h, cells are labeled with DCF-DA probe and its fluorescence is quantified and related to control. 103 
As shown in Figures 3 (1 h, 3 h) and 4 (24 h) no fluorescence variations after TMAO treatment is 104 
detected at any concentration and time used. As a positive control we employ DOX 1µM for 24 h [15]; 105 
this drug caused a significant variation in ROS production referred to control condition. TMAO  106 
100µM does not modify ROS production in DOX treated cardiomyocytes (Fig. 4). (1h: TMAO 100µM: 107 
1.30±0.21, n=3, 34 cells; TMAO 10mM: 1.32±0.23, n=3, 40 cells, vs CTRL; 3h: TMAO 100µM: 0.96±0.05, 108 
n=3, 45 cells; TMAO 10mM: 1.15±0.09, n=3, 52 cells, vs CTRL; 24h: TMAO 100µM: 1.18±0.04, n=5, 40 109 
cells; TMAO 10mM: 1.24±0.16, n=3, 52 cells; DOX: 1.33±0.11, n=4, 21 cells (**P<0.01); DOX+TMAO: 110 
1.27±0.01, n=6, 31 cells (***P<0.001) vs CTRL).  111 
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Figure 3. ROS production after 1 h and 3 h of treatment. a) Confocal microscopy images of cells treated 114 
with TMAO 100µM and TMAO 10mM for 1 h and 3 h and labeled with DCF-DA probe (60X 115 
magnification). b) Bar graph showing mean fluorescence after 1 h and 3 h of treatment, no variations 116 
or ROS produced are detectable (refer to the main text for numerical values). 117 
 118 
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 15 
 
 119 
Figure 4. ROS production after 24 h of treatment. a) Confocal microscopy images of cells treated with 120 
TMAO 100µM and TMAO 10mM for 24 h and labeled with DCF-DA probe. In these experiments 121 
Doxorubicin (DOX) is used as positive control (60X magnification). b) Bar graph showing mean 122 
fluorescence after 24 h of treatment. No variations of ROS produced are detectable after TMAO 123 
treatment, and a small but significant increase is visible after DOX treatment (here used as positive 124 
control), this increase is not changed by a simultaneous treatment with TMAO (refer to the main text 125 
for numerical values). 126 
2.4 TMAO and mitochondrial membrane potential  127 
To investigate the potential metabolic damage induced by TMAO, cardiomyocytes treated with 128 
TMAO 100µM and 1mM for 1 h, 3 h or 24 h are labeled with the JC-1 probe. Figures 5 (1 h, 3 h) and 6 129 
(24 h) show variations in mitochondrial membrane potential (red/green fluorescence ratio) detected 130 
by confocal microscopy in living cells. TMAO treatment from 1 to 24 h does not cause any difference 131 
towards control, indicating no mitochondrial effect of the molecule, while, as expected, DOX cause a 132 
depolarization of mitochondrial membrane potential after 24 h of treatment. TMAO 100µM does not 133 
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modify mitochondrial membrane potential in DOX treated cardiomyocytes (Fig. 6) (1 h: TMAO 134 
100µM: 1.09±0.08, n=5, 65 cells; TMAO 10mM: 1.11±0.11, n=3, 49 cells, vs CTRL. 3 h: TMAO 100µM: 135 
1.02±0.06, n=3, 26 cells; TMAO 10mM: 0.88±0.05, n=4, 39 cells, vs CTRL; 24 h: TMAO 100µM: 1.08±0.11, 136 
n=3, 21 cells; TMAO 10mM: 0.95±0.15, n=3, 54 cells; DOX: 0.73±0.02, n=3, 24 cells (**P<0.01); 137 
DOX+TMAO: 0.69±0.05, n=3, 22 cells (**P<0.01), vs CTRL). 138 
 139 
 140 
Figure 5. Mitochondrial membrane potential variation following 1 h and 3 h of treatment. a) Confocal 141 
microscopy images of cells treated with TMAO 100µM and TMAO 10mM for 1 h and 3 h and labeled 142 
with JC-1 probe (60X magnification). b) Bar graph showing red/green fluorescence after 1 h and 3 h 143 
of treatment, no variations of mitochondrial membrane potential is detected (refer to the main text for 144 
numerical values). 145 
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Figure 6. Mitochondrial membrane potential variation following 24 h treatment. a) Confocal 148 
microscopy images of cells treated with TMAO 100µM and TMAO 10mM for 24 h and labeled with 149 
JC-1 probe. In these experiments Doxorubicin (DOX) is used as positive control (60X magnification). 150 
b) Bar graph showing red/green fluorescence after 24 h of treatment, no variations of mitochondrial 151 
membrane potential is detected, a little but significant reduction of the ratio is visible after DOX 152 
treatment here used as positive control, condition not changed in a simultaneous treatment with 153 
TMAO (refer to the main text for numerical values). 154 
 155 
3. Discussion 156 
This study provides novel insights into the physiological role of TMAO on isolated adult rat 157 
cardiomyocytes. Our findings do not show effects of TMAO on cell viability, sarcomere length, ROS 158 
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production and mitochondrial membrane potential within the range of concentration used. 159 
Moreover, we demonstrate that TMAO does not exacerbate or counteract the effect of known insults 160 
such as H2O2 or Doxorubicin, tested for up to 24 h of treatment. Taken together these results suggest 161 
that TMAO should not be considered a primary cause of acute cardiac damage and that the molecule 162 
could not revert or worsen existing risk factors of cardiac damage.  163 
In the last few years, many studies suggest a strong relationship among diet, gut microbiota and 164 
cardiovascular diseases [16]. In particular, some attention has been pointed to either TMAO directly 165 
coming from diet (fish), or produced from L-carnitine and choline conversion by gut microbiota into 166 
TMA and oxidized in the liver by FMO3 enzymes [17, 14]. 167 
Experiments have mainly now focused on endothelial cells damaging role of TMAO. It has been 168 
described to upregulate cellular senescence reducing cell proliferation, increasing the expression of 169 
senescence markers, as p53 and p21, and impairing cell migration [3]. TMAO also increases 170 
endothelial cells oxidative stress through a down-regulation of SIRT-1 and impairs NO production 171 
that causes endothelial dysfunction [4]. Prolonged hypertensiveHypertensive effects of TMAO 172 
angiotensin II have been evaluated by Ufnal and colleagues who demonstrate that TMAO has a role 173 
in stabilizing the action of Ang II and in prolonging its hypertensive effect, underlining the role of 174 
TMAO in stabilizing protein conformation and no direct role of the molecule in mediating 175 
hypertension promoting this condition [18]. Koeth and colleagues underline the strong relationship 176 
among high consumption of TMAO precursors, high TMAO plasma concentrations and the 177 
development of atherosclerosis [19], while another study underlines the effect of the metabolite in 178 
enhancing platelet hyperreactivity and thrombosis risk in subjects with high TMAO plasma 179 
concentrations [5]. In relation with cardiovascular effects of TMAO, Dambrova and collaborators 180 
evidence that high plasma concentrations of the molecule are linked with increased body weight, 181 
insulin resistance and it directly correlates with an augmented risk of diabetes [20]. 182 
Only a few studies are centered on the direct effect of the molecule on cardiac cells; in particular 183 
they focus on the impairment of mitochondrial metabolism in the heart and underline TMAO as an 184 
agent that increases the severity of cardiovascular events or that enhances the progression of 185 
cardiovascular diseases [7]. Savi et colleagues show a damaging effect of TMAO in cardiomyocytes 186 
because it worsens intracellular calcium handling with a reduced efficiency in the intracellular 187 
calcium removal and consequent loss in functionality of cardiac cells, furthermore TMAO seems to 188 
alter energetic metabolism and to facilitate protein oxidative damage [8].  189 
This scenario presents TMAO as either a marker or a direct agent involved in vascular and 190 
cardiac outcomes, but recent papers seem to oppose this point of view, highlighting uncertainty about 191 
the causative relation between TMAO and CVD [9]. It is still debated the function of TMAO that is, 192 
for example, controversial in fish-rich diets, because of the higher bioavailability of the compound in 193 
seafood products and their well-known role in lowering risk of CVD. Also, TMAO does not enhance 194 
atherosclerosis development because it seems not to be involved in foam cell formation even at higher 195 
concentrations than physiological ones [12], and, there is no direct correlation between high plasma 196 
TMAO concentrations and coronary heart diseases [21, 22]. Last findings by Huc et al., underline also 197 
a protective role of TMAO in reducing diastolic dysfunction and fibrosis in pressure-overloaded heart 198 
[23]. 199 
The present study fits into this debate and the results presented agree with other works 200 
supporting TMAO as a non-damaging factor. In fact, it is well known that loss of vital cardiac cells is 201 
a damaging condition that hampers primarily the functionality of the heart and has several 202 
aggravating responses also in peripheral tissues. Our first investigations underline no toxic effect in 203 
cardiomyocytes exposed to high concentrations of TMAO highlighting that the molecule is not 204 
involved in inducing cardiac tissue cells loss (Fig. 1), and, no alterations of cardiac structure emerge 205 
from the evaluation of sarcomere length and cytoskeletal organization (Fig. 2). Oxidative stress could 206 
be considered one of the causative factors of senescence in cells, and one of the promoters of 207 
cardiometabolic reorganization in response to injury. Considering TMAO as a possible inducer of 208 
ROS rising, both in cytoplasmic and mitochondrial environment, we show no variation in ROS 209 
production even after 24 h of treatment (Fig. 3 and 4) and we detect no depolarization of 210 
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mitochondrial membrane potential underling no direct influence of the molecule in inducing cardiac 211 
cell senescence (Fig. 5 and 6). 212 
4. Materials and Methods  213 
4.1 Animal care and sacrifice  214 
Experiments are performed on female adult rats which are allowed ad libitum access to tap water 215 
and standard rodent diet. The animals receive human care in compliance with the Guide for the Care 216 
and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 217 
No. 85-23, revised 1996), and in accordance with Italian law (DL-116, Jan. 27, 1992). The scientific 218 
project is supervised and approved by the Italian Ministry of Health, Rome, and by the ethical 219 
committee of the University of Torino. Rats are anaesthetized by i.p. injection of Pentobarbital 220 
(Nembutal, 100 mg/Kg) and killed by stunning and cervical dislocation.  221 
4.2 Solutions and drugs  222 
Tyrode standard solution containcontaining (in mM): 154 NaCl, 4 KCl, 1 MgCl2, 5.5 D-glucose, 223 
5 HEPES, 2 CaCl2, pH adjusted to 7.34 with NaOH. Ca2+ free Tyrode solution contain (in mM): 154 224 
NaCl, 4 KCl, 1 MgCl2, 5.5 D-glucose, 5 HEPES, 10 2,3-Butanedione monoxime, 5 taurine, pH 7.34. All 225 
drug-containing solutions are prepared fresh before the experiments and Tyrode solutions are 226 
oxygenated (O2 100%) before each experiment. Unless otherwise specified, all reagents for cells 227 
isolation and experiments are purchased from Sigma-Aldrich.  228 
4.3 Adult rat ventricular cells isolation  229 
Isolated cardiomyocytes are obtained from the hearts of adult rats (200–300 g body wt) according 230 
to the previously described method [2324]. Briefly, after sacrifice, the rat hearts are explanted, washed 231 
in Ca2+ free Tyrode solution and cannulated via the aorta. All the following operations are carried on 232 
under a laminar flow hood. The heart is perfused at a constant flow rate of 10 ml/min with Ca2+ free 233 
Tyrode solution (37°C) with a peristaltic pump for approximately 5 min to wash away the blood and 234 
then with 10 ml of Ca2+ free Tyrode supplemented with collagenase (0.3mg/ml) and protease 235 
(0.02mg/ml). Hearts are then perfused and enzymatically dissociated with 20ml of Ca2+ free Tyrode 236 
containing 50µM CaCl2 and the same enzymatic concentration as before. Atria and ventricles are then 237 
separated and the ventricles are cut in small pieces and shaken for 10 minutes in 20ml of Ca2+ free 238 
Tyrode solution in presence of 50µM CaCl2, collagenase and protease. Calcium ions concentration is 239 
slowly increased to 0.8mM. Cardiomyocytes are then plated on glass cover slips or glass bottom 240 
dishes (Ibidi, Germany), both treated with laminin to allow cell adhesion.  241 
4.4 Cell viability  242 
Cell viability is evaluated by propidium iodide (PI) staining on glass bottom dishes adherent 243 
cells. At the end of the treatments cells are incubated with PI (10µg/ml, Invitrogen) for 5 min in the 244 
dark. Nuclei of suffering cells are detected with confocal microscopy using Olympus Fluoview 200 245 
microscope at 568nm (magnification 20X). Merged images are created with ImageJ (Rasband, W. S., 246 
ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-247 
2017) and cells viability is calculated as percentage of (total cells-labeled cells)/total cells. 248 
4.5 Evaluation of sarcomere length 249 
Cardiomyocytes on glass coverslips are stimulated with TMAO and H2O2, as a positive control. 250 
Cells are treated for 24 h with TMAO, at 100µM and 10mM, then the sarcomere protein α-actinin, 251 
localized in the Z lines, has been detected using confocal microscopy. Then cells are fixed in 4% PFA 252 
for 40 min. After two washes with PBS, cells are incubated for 20 min with 0.3% Triton and 1% bovine 253 
serum albumin (BSA) in PBS and stained for 24 h at +4°C with a mouse monoclonal anti-α-actinin 254 
primary antibody (Sigma, 1:800). Cover slides are washed twice with PBS and incubated 1 h at room 255 
Formatted: Strikethrough
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 11 of 15 
 
temperature with the secondary antibody (1:2000, anti-mouse Alexa Fluor 568, Thermo Fisher). After 256 
two washes in PBS, coverslips are mounted on standard slides with DABCO and observed after 24 h 257 
under confocal microscope. Confocal fluorimetric measurements are acquired using a Leica SP2 laser 258 
scanning confocal system, equipped with a 40X water-immersion objective. Image processing and 259 
analysis are performed with ImageJ software. Sarcomere length is evaluated measuring the distance 260 
between Z lanes in n=10 sarcomeres/cell.  261 
4.6 Intracellular Reactive Oxygen Species (ROS) measurement 262 
Production of ROS is evaluated by fluorescence microscopy using the 2’-7’-Dichlorofluorescein 263 
diacetate probe (DCF-DA). After adhesion on glass bottom dishes, DCF-DA solution (5µg/ml) is 264 
added to each dish 30min prior to the end of the treatment, then cells are washed with standard 265 
Tyrode solution. Fluorescence images at 488nm have been acquired with Olympus Fluoview 200 266 
microscope (magnification 60X). Fluorescence variations are calculated with the definition and 267 
measurement of Regions Of Interest (ROIs) using the software ImageJ and expressed as relative 268 
Medium Fluorescence Index (MFI) compared to control, fixed at 1. 269 
 4.7 Mitochondrial membrane potential measurement 270 
Mitochondrial membrane potential is evaluated by staining cardiomyocytes with the dye 271 
5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide (JC-1). JC-1 solution (10µM) is 272 
added to each dish 30 min prior to the end of the treatment, then cells are washed with Tyrode 273 
standard. Fluorescence images at 488nm and 568nm have been acquired with Olympus Fluoview 200 274 
microscope (magnification 60X). Amounts of the monomeric form of the dye are quantified using the 275 
red/green fluorescence ratio in the ROIs using the software ImageJ and expressed as folds towards 276 
control, fixed at 1.  277 
4.8 StatiticalStatistical analysis 278 
All data are expressed as mean±Standard Errors of the mean. For differences between mean 279 
values Bonferroni’s multiple comparisons test has been performed. Differences with P<0.05 are 280 
regarded as statistically significant.   281 
5. Conclusions 282 
In summary, this study demonstrates that TMAO is not directly involved in causing or 283 
exacerbating cardiac damage in an acute stress model (Fig. 7). However, there are some limitation of 284 
this study: a very wide range of plasmatic TMAO concentrations is presented in literature, and even 285 
within different mammals, and also between different sexes of the same species, several orders of 286 
magnitude can be considered physiological [24, 25, 26], so, to test direct effect of the molecule, it has 287 
been used high concentrations, even over human physiological ones. Another weakness of the study 288 
could be linked to the time of treatment, because evaluations are no longer than 24 h and they could 289 
only represent an acute exposure to TMAO. InMoreover, in order to evaluate more deeply the 290 
mechanism involved in TMAO-mediated responses it could be necessary to treat cells for longer time 291 
to assess a chronic stress compatible with the development of CVD. Furthermore we only study 292 
TMAO effect on female ventricular cardiomyocytes and it could be interesting to extend the analysis 293 
also to male cardiomyocytes as gender differences have been observed in cardioprotective 294 
mechanisms [27] and TMAO induced intracellular calcium imbalance has been described in male 295 
cardiomyocytes [8]. Finally, our findings provide new insights into cardiac effect of TMAO, exploring 296 
the direct treatment of isolated cardiomyocytes. 297 
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 298 
Figure 7. No effects of TMAO is detectable on isolated adult rat cardiomyocytes viability, sarcomere 299 
length, ROS production and mitochondrial membrane potential (MMP). 300 
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TMAO Trimethylamine N-oxide 
PI Propidium iodide 
ROS Reactive Oxygen Species 
DCF-DA 2’-7’-Dichlorofluorescein diacetate 
JC-1 5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide 
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